Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release

Brain Res Bull. 2006 Jan 30;68(5):361-73. doi: 10.1016/j.brainresbull.2005.09.018. Epub 2005 Oct 17.

Abstract

The autoinhibitory control of electrically evoked release of [3H]-dopamine and the properties of that induced by nicotinic receptor (nAChR) stimulation were studied in slices of the human neocortex. In both models [3H]-dopamine release was action potential-induced and exocytotic. The selective dopamine D2 receptor agonist (-)-quinpirole reduced electrically evoked release of [3H]-dopamine, yielding IC50 and I(max) values of 23 nM and 76%, respectively. Also, the effects of several other subtype-selective dopamine receptor ligands confirmed that the terminal dopamine autoreceptor belongs to the D2 subtype. The autoinhibitory feedback control was slightly operative under stimulation conditions of 90 pulses and 3 Hz, with a biophase concentration of endogenous dopamine of 3.6 nM, and was enhanced under blockade of dopamine reuptake. [3H]-dopamine release evoked in an identical manner in mouse neocortical slices was not inhibited by (-)-quinpirole, suggesting the absence of dopamine autoreceptors in this tissue and underlining an important species difference. Also, nAChR stimulation-induced release of [3H]-dopamine revealed a species difference: [3H]-dopamine release was evoked in human, but not in rat neocortical slices. The nAChRs inducing [3H]-dopamine release most probably belong to the alpha3/beta2subtype, according to the potencies and efficacies of subtype-selective nAChR ligands. Part of these receptors may be located on glutamatergic neurons.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / analogs & derivatives
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Adolescent
  • Adult
  • Aged
  • Alkaloids / pharmacology
  • Analysis of Variance
  • Animals
  • Autoreceptors / physiology*
  • Azocines / pharmacology
  • Calcium / pharmacology
  • Child
  • Child, Preschool
  • Domperidone / pharmacology
  • Dopamine / metabolism*
  • Dopamine Antagonists / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Electric Stimulation / methods
  • Feedback / drug effects
  • Female
  • Fluvoxamine / pharmacology
  • Humans
  • In Vitro Techniques
  • Isoxazoles / pharmacology
  • Male
  • Maprotiline / analogs & derivatives
  • Maprotiline / pharmacology
  • Mice
  • Middle Aged
  • Neocortex / drug effects
  • Neocortex / metabolism*
  • Neocortex / radiation effects
  • Nicotine / pharmacology
  • Nicotinic Antagonists / pharmacology
  • Potassium / pharmacology
  • Pyrrolidines / pharmacology
  • Quinolizines / pharmacology
  • Rats
  • Receptors, Nicotinic / physiology*
  • Sulpiride / pharmacology
  • Time Factors
  • Tritium / metabolism

Substances

  • Alkaloids
  • Autoreceptors
  • Azocines
  • Dopamine Antagonists
  • Isoxazoles
  • Nicotinic Antagonists
  • Pyrrolidines
  • Quinolizines
  • Receptors, Nicotinic
  • Tritium
  • 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole
  • 1,2,3,6-tetrahydro-4-phenyl-1-((3-phenyl-3-cyclohexen-1-yl)methyl)pyridine
  • Maprotiline
  • hydroxymaprotilin
  • cytisine
  • Domperidone
  • Nicotine
  • Sulpiride
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Fluvoxamine
  • Potassium
  • Calcium
  • Dopamine